Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Rezolute, Inc. - Common Stock (NV) (NQ:RZLT)

6.310 -0.160 (-2.47%)
Streaming Delayed Price Updated: 10:53 AM EDT, Aug 20, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 91,986
Open 6.360
Bid (Size) 6.300 (1)
Ask (Size) 6.330 (1)
Prev. Close 6.470
Today's Range 6.230 - 6.460
52wk Range 2.215 - 6.645
Shares Outstanding 57,943,066
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Rezolute Appoints Seasoned Commercial Executive Sunil Karnawat as Chief Commercial Officer
Experienced commercial and biopharmaceuticals leader to spearhead launch strategy and global market readiness for ersodetug 
From Rezolute, Inc.
Via GlobeNewswire
10 Health Care Stocks Whale Activity In Today's Session
 
Via Benzinga

Performance

YTD
+22.5%
+22.5%
1 Month
+17.3%
+17.3%
3 Month
+59.7%
+59.7%
6 Month
+32.3%
+32.3%
1 Year
+47.4%
+47.4%

More News

Read More
Rezolute to Participate in the BTIG Virtual Biotechnology Conference
From Rezolute, Inc.
Via GlobeNewswire
Rezolute Announces Presentation of Participant Baseline Data from its Fully Enrolled Phase 3 Study of Ersodetug in Congenital Hyperinsulinism at the Upcoming Annual Meeting of the Endocrine Society (ENDO 2025)
From Rezolute, Inc.
Via GlobeNewswire
Rezolute Announces Completion of Enrollment in the Phase 3 sunRIZE Study of Ersodetug in Patients with Congenital Hyperinsulinism
From Rezolute, Inc.
Via GlobeNewswire
Rezolute Reports Third Quarter Fiscal 2025 Financial Results and Provides Business Update
From Rezolute, Inc.
Via GlobeNewswire
Rezolute Receives Breakthrough Therapy Designation from FDA for Ersodetug in the Treatment of Hypoglycemia Due to Tumor Hyperinsulinism
From Rezolute, Inc.
Via GlobeNewswire
Rezolute to Participate in Upcoming Investor Conferences
From Rezolute, Inc.
Via GlobeNewswire
Rezolute, Inc. Announces Closing of Underwritten Offering
From Rezolute, Inc.
Via GlobeNewswire
Rezolute 'Thrilled' With Positive Review Of Genetic Disorder Trial, Expects Topline Results In December
Via Benzinga
The market is filled with gapping stocks in Wednesday's session.
Via Chartmill
What's going on in today's pre-market session
Via Chartmill
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Via Benzinga
Rezolute Announces Pricing of Offering of $90 Million of Common Stock and Pre-Funded Warrants
From Rezolute, Inc.
Via GlobeNewswire
Rezolute Announces Positive Recommendation After Independent Interim Analysis of Phase 3 sunRIZE Study of Ersodetug in Congenital Hyperinsulinism (“HI”)
From Rezolute, Inc.
Via GlobeNewswire
Top movers analysis in the middle of the day on 2025-04-21: top gainers and losers in today's session.
Via Chartmill
12 Health Care Stocks Moving In Monday's Intraday Session
Via Benzinga
Rezolute Announces Appointment of Rare Disease Commercial Leader Erik Harris to its Board of Directors
From Rezolute, Inc.
Via GlobeNewswire
Why AZEK Shares Are Trading Higher By Around 18%; Here Are 20 Stocks Moving Premarket
Via Benzinga
Rezolute Reports Second Quarter Fiscal 2025 Financial Results and Provides Business Update
From Rezolute, Inc.
Via GlobeNewswire
Rezolute Provides Update on its Phase 3 sunRIZE Study of Ersodetug for the Treatment of Hypoglycemia Due to Congenital Hyperinsulinism
From Rezolute, Inc.
Via GlobeNewswire
Rezolute to Participate in the Guggenheim SMID Cap Biotech Conference
From Rezolute, Inc.
Via GlobeNewswire
Rezolute Receives Breakthrough Therapy Designation from FDA for Ersodetug in the Treatment of Hypoglycemia Due to Congenital Hyperinsulinism
From Rezolute, Inc.
Via GlobeNewswire
Rezolute Reports Inducement Award Under Nasdaq Listing Rule 5635(c)(4)
From Rezolute, Inc.
Via GlobeNewswire
FDA Grants Orphan Drug Designation to Rezolute’s Ersodetug (RZ358) for the Treatment of Hypoglycemia Due to Tumor Hyperinsulinism
From Rezolute, Inc.
Via GlobeNewswire

Frequently Asked Questions

Is Rezolute, Inc. - Common Stock (NV) publicly traded?
Yes, Rezolute, Inc. - Common Stock (NV) is publicly traded.
What exchange does Rezolute, Inc. - Common Stock (NV) trade on?
Rezolute, Inc. - Common Stock (NV) trades on the Nasdaq Stock Market
What is the ticker symbol for Rezolute, Inc. - Common Stock (NV)?
The ticker symbol for Rezolute, Inc. - Common Stock (NV) is RZLT on the Nasdaq Stock Market
What is the current price of Rezolute, Inc. - Common Stock (NV)?
The current price of Rezolute, Inc. - Common Stock (NV) is 6.310
When was Rezolute, Inc. - Common Stock (NV) last traded?
The last trade of Rezolute, Inc. - Common Stock (NV) was at 08/20/25 10:53 AM ET
What is the market capitalization of Rezolute, Inc. - Common Stock (NV)?
The market capitalization of Rezolute, Inc. - Common Stock (NV) is 365.62M
How many shares of Rezolute, Inc. - Common Stock (NV) are outstanding?
Rezolute, Inc. - Common Stock (NV) has 366M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.